JP2010503687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503687A5 JP2010503687A5 JP2009528336A JP2009528336A JP2010503687A5 JP 2010503687 A5 JP2010503687 A5 JP 2010503687A5 JP 2009528336 A JP2009528336 A JP 2009528336A JP 2009528336 A JP2009528336 A JP 2009528336A JP 2010503687 A5 JP2010503687 A5 JP 2010503687A5
- Authority
- JP
- Japan
- Prior art keywords
- ephb receptor
- isolated
- binding compound
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000050554 Eph Family Receptors Human genes 0.000 claims 19
- 108091008815 Eph receptors Proteins 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 108010055334 EphB2 Receptor Proteins 0.000 claims 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 claims 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 claims 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 claims 1
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 claims 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84485106P | 2006-09-15 | 2006-09-15 | |
| PCT/US2007/020200 WO2008100288A2 (en) | 2006-09-15 | 2007-09-14 | High affinity ephb receptor binding compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503687A JP2010503687A (ja) | 2010-02-04 |
| JP2010503687A5 true JP2010503687A5 (https=) | 2010-11-04 |
Family
ID=39690647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009528336A Withdrawn JP2010503687A (ja) | 2006-09-15 | 2007-09-14 | 高親和性ＥｐｈＢ受容体結合化合物とその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100150834A1 (https=) |
| EP (1) | EP2061489A4 (https=) |
| JP (1) | JP2010503687A (https=) |
| AU (1) | AU2007347182A1 (https=) |
| CA (1) | CA2662684A1 (https=) |
| WO (1) | WO2008100288A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528614A (ja) | 2005-01-27 | 2008-07-31 | ザ・バーンハム・インスティテュート | ＥｐｈＢ受容体結合ペプチド |
| US20120202890A1 (en) * | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| EP3966567A4 (en) | 2019-05-08 | 2023-01-25 | Board of Regents, The University of Texas System | THERAPEUTIC PEPTIDES |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE240740T1 (de) * | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| IL143558A0 (en) * | 1998-12-23 | 2002-04-21 | Regeneron Pharma | Method of enhancing the biological activity of ligands |
| DE19919148A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| US7101976B1 (en) * | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| US7919118B2 (en) * | 2003-05-12 | 2011-04-05 | Affymax, Inc. | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
| US20050147593A1 (en) * | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
| JP2008528614A (ja) * | 2005-01-27 | 2008-07-31 | ザ・バーンハム・インスティテュート | ＥｐｈＢ受容体結合ペプチド |
| WO2007082296A2 (en) * | 2006-01-12 | 2007-07-19 | The Scripps Research Institute | Crystal of a receptor-ligand complex and methods of use |
-
2007
- 2007-09-14 WO PCT/US2007/020200 patent/WO2008100288A2/en not_active Ceased
- 2007-09-14 CA CA002662684A patent/CA2662684A1/en not_active Abandoned
- 2007-09-14 AU AU2007347182A patent/AU2007347182A1/en not_active Abandoned
- 2007-09-14 JP JP2009528336A patent/JP2010503687A/ja not_active Withdrawn
- 2007-09-14 EP EP07872617A patent/EP2061489A4/en not_active Withdrawn
- 2007-09-14 US US12/441,274 patent/US20100150834A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502810A5 (https=) | ||
| CN102272159B (zh) | 结合SPARC的ScFv | |
| JP2020508691A5 (https=) | ||
| US20230272033A1 (en) | Epha3 and multi-valent targeting of tumors | |
| JP2008503217A5 (https=) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2022537054A (ja) | 多鎖キメラポリペプチドおよびその使用 | |
| JP2006515363A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2020530285A5 (https=) | ||
| CN104130315A (zh) | 一种特异靶向her2蛋白的多肽 | |
| JP2005528884A5 (https=) | ||
| JP2009505964A5 (https=) | ||
| JP2019520038A5 (https=) | ||
| CA2579523A1 (en) | Atad3a-binding molecules for treatment, detection and prevention of cancer | |
| JP2004512010A5 (https=) | ||
| US20190211088A1 (en) | Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells | |
| WO2016207402A1 (en) | Proteins comprising a mutated lair-1 fragment and uses thereof | |
| CN107556367B (zh) | 一种肿瘤免疫治疗预测生物标志物pd-l2靶向多肽及其应用 | |
| JP2010503687A5 (https=) | ||
| JP2004533825A5 (https=) | ||
| CN105713094B (zh) | 一种cd24抗体融合蛋白的设计及其应用 | |
| JP7766489B2 (ja) | 免疫調節特性を有するペプチド | |
| JP2015533372A5 (https=) | ||
| JP2008516985A5 (https=) |